Table 2.

Univariate and multivariable analysis of induction failure

VariableMultivariable analysis, n = 227Model selectionUnivariate analysisEvaluable patients, n
OR (95% CI)POR (95% CI)POR (95% CI)P
PS29MRCdic 3.47 (1.65-7.39) 1.09 × 10−3 3.54 (1.74-7.33) .00054 4.81 (2.95-7.93) 4.15 × 10−10 351 
Retrained response LSC17 1.00 (1.00-1.00) .65   1.001 (1.000-1.002) .046 360 
Age continuous 1.03 (1.00-1.06) .044 1.03 (1.00-1.05) .043 1.04 (1.02-1.06) 1.37 × 10−4 375 
Secondary AML 1.06 (0.45-2.43) .89   1.70 (0.96-2.94) .063 375 
NPM1mut 0.81 (0.34-1.93) .64   0.49 (0.29-0.79) 4.80 × 10−3 372 
RUNX1mut 1.27 (0.46-3.44) .64   2.58 (1.24-5.35) .011 238 
TP53mut 0.67 (0.16-2.75) .58   2.62 (0.93-7.43) .065 237 
ASXL1mut 0.97 (0.34-2.75) .96   2.21 (0.98-4.87) .051 237 
ELN-2017fav 0.41 (0.12-1.39) .15 0.33 (0.13-0.81) .016 0.17 (0.09-0.32) 5.72 × 10−8 319 
ELN-2017int 0.94 (0.33-2.70) .91 0.88 (0.41-1.92) .75 0.50 (0.26-0.94) .033 319 
VariableMultivariable analysis, n = 227Model selectionUnivariate analysisEvaluable patients, n
OR (95% CI)POR (95% CI)POR (95% CI)P
PS29MRCdic 3.47 (1.65-7.39) 1.09 × 10−3 3.54 (1.74-7.33) .00054 4.81 (2.95-7.93) 4.15 × 10−10 351 
Retrained response LSC17 1.00 (1.00-1.00) .65   1.001 (1.000-1.002) .046 360 
Age continuous 1.03 (1.00-1.06) .044 1.03 (1.00-1.05) .043 1.04 (1.02-1.06) 1.37 × 10−4 375 
Secondary AML 1.06 (0.45-2.43) .89   1.70 (0.96-2.94) .063 375 
NPM1mut 0.81 (0.34-1.93) .64   0.49 (0.29-0.79) 4.80 × 10−3 372 
RUNX1mut 1.27 (0.46-3.44) .64   2.58 (1.24-5.35) .011 238 
TP53mut 0.67 (0.16-2.75) .58   2.62 (0.93-7.43) .065 237 
ASXL1mut 0.97 (0.34-2.75) .96   2.21 (0.98-4.87) .051 237 
ELN-2017fav 0.41 (0.12-1.39) .15 0.33 (0.13-0.81) .016 0.17 (0.09-0.32) 5.72 × 10−8 319 
ELN-2017int 0.94 (0.33-2.70) .91 0.88 (0.41-1.92) .75 0.50 (0.26-0.94) .033 319 

fav, favorable risk; int, intermediate risk; mut, mutated; P-values marked in bold indicate numbers that are significant (P < .05).

Close Modal

or Create an Account

Close Modal
Close Modal